Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients.

Hideyuki TamaiNaoki ShingakiYoshiyuki IdaRyo ShimizuShuya MaeshimaJunpei OkamuraAkira KawashimaTaisei NakaoTakeshi HaraHiroyoshi MatsutaniIzumi NishikawaKatsuhiko Higashi

Published in: JGH open : an open access journal of gastroenterology and hepatology (2018)

In this real-world setting, sofosbuvir and ledipasvir were a safe treatment even in patients ≥75 years old. When patients without pre-existing NS5A RASs and daclatasvir plus asunaprevir failure are selected, extremely high SVR rates can be achieved irrespective of age.

Keyphrases

hepatitis c virus
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
zika virus
replacement therapy